Showing 7461-7470 of 8856 results for "".
- Pulsed-Dye Laser Reduces the Effects of Hypertrophic Scars Post-thyroidectomyhttps://practicaldermatology.com/news/pulsed-dye-laser-reduces-the-effects-of-hypertrophic-scars-post-thyroidectomy/2461308/Treatment with a 595 nm pulsed dye laser (PDL) can prevent and improve hypertrophic scars in patients with post-thyroidectomy in a cost-effective fashion, a new study shows. For the study, 19 patients with hypertrophic scars after thyroidectomy underwent
- Epidural Nerve Block with Lidocaine Leads to Clearance of Psoriatic Skin Lesionshttps://practicaldermatology.com/news/epidural-nerve-block-with-lidocaine-leads-to-clearance-of-psoriatic-skin-lesions/2461297/Use of an epidural nerve block with lidocaine leads to clearance of psoriatic skin lesions, according to a novel proof-of-concept study in the Journal of Investigative Dermatology. “Case studies have shown that psoriasis patients have experienced significant symptom
- FDA Cracks Down on Three Companies for Selling Unapproved New Drugs for Mole and Skin Tag Removalhttps://practicaldermatology.com/news/fda-cracks-down-on-three-companies-for-selling-unapproved-new-drugs-for-mole-and-skin-tag-removal/2461294/The U.S. Food and Drug Administration issued three warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). There are no FDA-appr
- Pulse Biosciences Scores FDA 510(k) Clearance of Expanded Energy Settings for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-fda-510k-clearance-of-expanded-energy-settings-for-cellfx-system/2461289/The U.S. Food and Drug Administration (FDA) gave 510(k) clearance tp expanded energy settings for use with Pulse Biosciences, Inc.’s CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatmen
- NRS Survey: Persistent Facial Redness Named Most Common and Bothersome Sign of Rosaceahttps://practicaldermatology.com/news/nrs-survey-persistent-facial-redness-is-the-most-common-and-bothersome-sign-of-rosacea/2461285/The great majority of rosacea patients have experienced persistent facial redness, and most of them report it is the most frequently bothersome sign they face, according to a recent National Rosacea Society (NRS) survey on rosacea redness sponsored by EPI Health. Furthermore, two-
- Survey: Chronic Hive Patients Unsatisfied with Quality of Life, Carehttps://practicaldermatology.com/news/survey-chronic-hive-patients-unsatisfied-with-quality-of-life/2461271/Only one-fourth of patients with chronic hives are satisfied with their current quality of life, according to a recent survey conducted by
- Novan's Berdazimer Gel Performs Well in Phase 3 for Molluscum: Studyhttps://practicaldermatology.com/news/novans-berdazimer-gel-performs-well-in-phase-3-for-molluscum-study/2461269/Berdazimer gel, 10.3% from Novan, Inc., significantly out-performed placebo for the treatment of molluscum, according to results of the B-SIMPLE 4 pivotal Phase 3 clinical study published in JAMA Dermatology</
- Lauren Miller, MPAS, PA-C Begins Term as SDPA Presidenthttps://practicaldermatology.com/news/lauren-miller-mpas-pa-c-begins-term-as-sdpa-president/2461267/Lauren Miller, MPAS, PA-C is president of the Society of Dermatology Physician Assistants Board of Directors. Ms. Miller, a DermPA™ with Dermatology Specialists in Gadsden, AL, will serve a one-year term leading the nine-member elected board. “I am honored and humbled t
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- Systemic Inhibition of S100A9 May Reduce Severity of PsO, PsAhttps://practicaldermatology.com/news/systemic-inhibition-of-s100a9-may-reduce-severity-of-pso-psa/2461262/The severity of psoriasis and psoriatic arthritis can be reduced by inhibiting S100A9 systemically throughout the whole body rather than locally on the skin, according to a new study. By way of background, S100A9 activation in skin and immune cells has been identified as a risk factor f